The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Go-ahead for pivotal clinical trial which is expected to commence by March
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
Second interchangeable biosimilar product approved by agency
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
CuraTeQ Biologics is on track for filing a second oncology biosimilar
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
